Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07471932) titled 'A Study of LAD106 in Healthy Adult Participants' on March 6.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
Primary Sponsor: Almirall, S.A.
Condition:
Healthy Volunteers
Intervention:
Drug: LAD106
Drug: Lebrikizumab
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: February 17, 2026
Target Sample Size: 93
Countries of Recruitment:
Netherlands
To know more, visit https://clinicaltrials.gov/study/NCT07471932
Published by HT Digital C...